PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer

Wu, C; Peng, S; Pilie, PG; Geng, CD; Park, S; Manyam, GC; Lu, YG; Yang, G; Tang, Z; Kondraganti, S; Wang, DQ; Hudgens, CW; Ledesma, DA; Marques-Piubelli, ML; Torres-Cabala, CA; Curry, JL; Troncoso, P; Corn, PG; Broom, BM; Thompson, TC

Thompson, TC (corresponding author), Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol Dept, 1515 Holcombe Blvd, Houston, TX 77030 USA.

MOLECULAR CANCER THERAPEUTICS, 2021; 20 (9): 1680

Abstract

We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi; olaparib) and CDK4/6 inhibition (CDK4/6i; palbociclib or abemaciclib)......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索